BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Teich N, Grümmer H, Jörgensen E, Liceni T, Holtkamp-Endemann F, Fischer T, Hohenberger S. Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results. World J Gastroenterol 2020; 26(21): 2852-2863 [PMID: 32550760 DOI: 10.3748/wjg.v26.i21.2852]
URL: https://www.wjgnet.com/1007-9327/full/v26/i21/2852.htm
Number Citing Articles
1
Niels Teich, Harald Grümmer, Eric Jörgensen, Thomas Liceni, Frank Holtkamp-Endemann, Tim Fischer, Susanne Hohenberger. Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 monthsBMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01747-z
2
Michael Youssef, Nariman Hossein-Javaheri, Tedi Hoxha, Christina Mallouk, Parul Tandon. Work Productivity Impairment in Persons with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysisJournal of Crohn's and Colitis 2024; 18(9): 1486 doi: 10.1093/ecco-jcc/jjae057
3
Marc Ferrante, Anja Schirbel, Marieke J. Pierik, Thomas Haas, Mathurin Flamant, Ahmed Khalifa, George Philip, Freddy Cornillie, Alan G. Meehan, Marinella Govoni. Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational studyEuropean Journal of Gastroenterology & Hepatology 2022; 34(6): 646 doi: 10.1097/MEG.0000000000002374
4
Anthia Gatopoulou, Dimitrios K. Christodoulou, Konstantinos H. Katsanos, Dimitrios Bakos, Ioannis Mouzas, Maria Tzouvala, Angeliki Theodoropoulou, Gregorios Paspatis, George Theocharis, Konstantinos Thomopoulos, Olga Giouleme, Anastasia Kourikou, Spilios Manolakopoulos, Evanthia Zampeli, Spyros Michopoulos, Pantelis Karatzas, Marios Katsaros, Dimitris Moschovis, Eleni Orfanoudaki, Achilleas Livieratos, Evangelia Petrikkou, Gerassimos J. Mantzaris. Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in GreeceEuropean Journal of Gastroenterology & Hepatology 2021; 33(1S): e615 doi: 10.1097/MEG.0000000000002182
5
Allie Cichewicz, Tom Tencer, Komal Gupte-Singh, Sonya Egodage, Heather Burnett, Jinender Kumar. A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative ColitisAdvances in Therapy 2023; 40(5): 2116 doi: 10.1007/s12325-023-02488-z
6
Talat Bessissow, Geoffrey C Nguyen, Osman Tarabain, Laurent Peyrin-Biroulet, Nathalie Foucault, Kevin McHugh, Joannie Ruel. Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA studyWorld Journal of Gastroenterology 2022; 28(34): 5058-5075 doi: 10.3748/wjg.v28.i34.5058
7
Daisuke Hirayama, Satoshi Motoya, Toshifumi Ashida, Katsuyoshi Ando, Mikihiro Fujiya, Takahiro Ito, Shigeru Furukawa, Atsuo Maemoto, Takehiko Katsurada, Shiro Hinotsu, Noriko Sato, Naomi Mizuno, Yoshiko Ikawa, Hiroshi Nakase. Effectiveness and Factors Associated with Response to Golimumab in Japanese Patients with Ulcerative Colitis in Real Clinical Practice: The Phoenix StudyInflammatory Intestinal Diseases 2023; 8(3): 115 doi: 10.1159/000533871